CMS opens national coverage determination analysis on Alzheimer’s treatment

The Centers for Medicare and Medicaid Services said this week it's opening a National Coverage Determination analysis, a process that will allow the agency to review and determine whether Medicare will establish a national coverage policy for monoclonal antibodies targeting amyloid for the treatment of Alzheimer's disease.

Read the full post at News Feed
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive